| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | July 23, 2026 | 5/12 | 2 high, 3 medium, 1 low flags | 2 | 2 | Call sheet → |
| Q1'26 | April 23, 2026 | 12/12 | 1 medium, 5 low flags | 3 | 1 | Call sheet → |
| Q4'25 | January 29, 2026 | 11/12 | 6 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Delivered | Lead times for heat exchangers extending with capacity coming online as year progresses Confirmed extending materially, capacity additions sequentially through H2 |
| Q2'26 | Pending | Driving to top end of guidance range based on order rates Raised EPS but not revenue guidance, mixed signal |
| Q2'26 | Missed | Midstream compression pickup beginning in second half Zero mention on Q2 call, appears to have been quietly dropped |
| Q2'26 | Pending | Incremental margin in climate segment to be robust in H2 after facility consolidation Still claiming this but pushed timeline to 'probably by midyear' |
| Q2'26 | Missed | Climate & sustainability to deliver double-digit organic growth for 2026 Only grew 8% in Q2, massive deceleration from 15% in Q1 |
| Q2'26 | Delivered | Expect gradual improvement in polymer processing supported by improved quoting activity Book-to-bill turned positive in Q2, signaling stabilization |
| Q1'26 | Delivered | Biopharma tough comp in Q1 2026 due to early 2025 restocking (Q4) DPS segment declined modestly as expected, lapped the difficult comparison |
| Q1'26 | Delivered | Seasonality consistent with recent years - Q1 lowest cash flow (Q4) Q1 at 6% of revenue vs Q4 at 23%, typical seasonal pattern maintained |
| Q1'26 | Delivered | Recovery in refrigerated door cases and services based on Q3 booking exit (Q4) Significant volume improvements delivered as promised in Q4 |
| Q1'26 | Missed | Climate segment margin inflection from facility consolidation (Q4) Consolidation delayed due to strong orders, now expected by midyear instead of Q1 |
| Q1'26 | Pending | Clean Energy & Fueling margin improvement on volume leverage (Q4) Margins actually down slightly in Q1 due to mix, back-half loaded improvement expected |
| Q1'26 | Pending | Double-digit adjusted EPS growth for full year 2026 (Q4 commitment) Reaffirmed commitment despite Q1 margin pressure, driving to top end of range |
| Q4'25 | Pending | Close on 'a couple of things' in M&A over next 12 months Timeline intact, management reiterates active pipeline and expected 2026 activity |
| Q4'25 | Delivered | Update on restructuring benefits by Q3 call Provided specific $40M carryover benefit quantification for 2026 |
| Q4'25 | Delivered | Biopharma to remain strong in Q4 after restocking concerns Confirmed consistent demand, not restocking, with solid Q4 performance |
| Q4'25 | Delivered | Margin improvement in Q4 despite some mix effects Segment EBITDA margins up 60 bps to 24.8% despite noted headwinds |
| Q4'25 | Delivered | Material acceleration in booking rates for refrigeration Bookings up 25% in Climate & Sustainability, driving Q4 revenue recovery |
| Q4'25 | Delivered | Q4 should be highest organic growth quarter of the year Achieved 5% organic growth, beating Q3's performance as promised |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.